Innovation, Science, Environment 07/08
Innovation, Science, Environment 07/08

Author: Carleton University. School of Public Policy and Administration

Publisher: McGill-Queen's Press - MQUP

Published: 2007

Total Pages: 320

ISBN-13: 0773532285

DOWNLOAD EBOOK

The impact of climate change is becoming increasingly obvious around the world but different levels of the Canadian government are failing to respond cohesively. For example, the Harper government immediately cut several liberal-era environmental research programs and admitted that Canada has been moving away from Kyoto Protocol targets and that the Kyoto Protocol is not central to its idea of either good environmental or good energy policy. Meanwhile, a Quebec liberal government announced that it would introduce a carbon tax to reduce CO2 emissions by 10 million tons by 2012 while Canada's mayors introduced their own climate change initiatives, linking them to local infrastructure development. This second volume in the ISE series examines the reshaping of ISE policy in the context of multi-level governance and policy. Contributors examine climate change policy, innovation in the natural resources sector, the internet pharmacy trade, biotechnology policy and governance, provincial government renewable energy policies, the psychological and human nature connection with sustainable development policies, procurement policy and innovation, the Canadian Institutes of Health Research, and the commercialization of Canada's universities.

Prescription Painkillers
Prescription Painkillers

Author: Marvin D Seppala

Publisher: Simon and Schuster

Published: 2011-01-25

Total Pages: 271

ISBN-13: 1592859933

DOWNLOAD EBOOK

The definitive book about the impact of prescription painkiller abuse on individuals, communities, and society by one of America's leading experts on addiction. In recent years, the media has inundated us with coverage of the increasing abuse of prescription painkillers. Prescription Painkillers, the third book in Hazelden's Library of Addictive Drugs series, offers current, comprehensive information on the history, social impact, pharmacology, and addiction treatment for commonly abused, highly addictive opiate prescription painkillers such as Oxycontin®, Vicodin, Percocet, and Darvocet. Marvin D. Seppala, MD, provides context for understanding the current drug abuse problem by tracing the history of opioids and the varying patterns of use over time. He then offers an in-depth study of controversial issues surrounding these readily available drugs, including over-prescription by physicians and adolescent abuse. Also included is a straightforward look at the leading treatment protocols based on current research.

Overview of the Privacy Act of 1974
Overview of the Privacy Act of 1974

Author: United States. Department of Justice. Privacy and Civil Liberties Office

Publisher:

Published: 2010

Total Pages: 276

ISBN-13:

DOWNLOAD EBOOK

The "Overview of the Privacy Act of 1974," prepared by the Department of Justice's Office of Privacy and Civil Liberties (OPCL), is a discussion of the Privacy Act's disclosure prohibition, its access and amendment provisions, and its agency recordkeeping requirements. Tracking the provisions of the Act itself, the Overview provides reference to, and legal analysis of, court decisions interpreting the Act's provisions.

Pain Management and the Opioid Epidemic
Pain Management and the Opioid Epidemic

Author: National Academies of Sciences, Engineering, and Medicine

Publisher: National Academies Press

Published: 2017-09-28

Total Pages: 483

ISBN-13: 0309459575

DOWNLOAD EBOOK

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.

Guide for All-Hazard Emergency Operations Planning
Guide for All-Hazard Emergency Operations Planning

Author: Kay C. Goss

Publisher: DIANE Publishing

Published: 1998-05

Total Pages: 277

ISBN-13: 078814829X

DOWNLOAD EBOOK

Meant to aid State & local emergency managers in their efforts to develop & maintain a viable all-hazard emergency operations plan. This guide clarifies the preparedness, response, & short-term recovery planning elements that warrant inclusion in emergency operations plans. It offers the best judgment & recommendations on how to deal with the entire planning process -- from forming a planning team to writing the plan. Specific topics of discussion include: preliminary considerations, the planning process, emergency operations plan format, basic plan content, functional annex content, hazard-unique planning, & linking Federal & State operations.

Countering the Problem of Falsified and Substandard Drugs
Countering the Problem of Falsified and Substandard Drugs

Author: Institute of Medicine

Publisher: National Academies Press

Published: 2013-06-20

Total Pages: 377

ISBN-13: 0309269393

DOWNLOAD EBOOK

The adulteration and fraudulent manufacture of medicines is an old problem, vastly aggravated by modern manufacturing and trade. In the last decade, impotent antimicrobial drugs have compromised the treatment of many deadly diseases in poor countries. More recently, negligent production at a Massachusetts compounding pharmacy sickened hundreds of Americans. While the national drugs regulatory authority (hereafter, the regulatory authority) is responsible for the safety of a country's drug supply, no single country can entirely guarantee this today. The once common use of the term counterfeit to describe any drug that is not what it claims to be is at the heart of the argument. In a narrow, legal sense a counterfeit drug is one that infringes on a registered trademark. The lay meaning is much broader, including any drug made with intentional deceit. Some generic drug companies and civil society groups object to calling bad medicines counterfeit, seeing it as the deliberate conflation of public health and intellectual property concerns. Countering the Problem of Falsified and Substandard Drugs accepts the narrow meaning of counterfeit, and, because the nuances of trademark infringement must be dealt with by courts, case by case, the report does not discuss the problem of counterfeit medicines.